© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Insulet Corp. (PODD) stock declined over -2.07%, trading at $136.49 on NASDAQ, down from the previous close of $139.38. The stock opened at $139.07, fluctuating between $134.73 and $139.82 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 23, 2026 | 139.07 | 139.82 | 134.73 | 136.49 | 1.02M |
| Sep 21, 2026 | 140.60 | 141.49 | 138.59 | 140.53 | 1.34M |
| Sep 18, 2026 | 141.25 | 142.17 | 139.96 | 140.60 | 2.49M |
| Sep 17, 2026 | 140.38 | 141.80 | 138.51 | 141.55 | 1.18M |
| Sep 16, 2026 | 138.86 | 143.45 | 138.11 | 140.60 | 1.31M |
| Sep 15, 2026 | 137.59 | 140.28 | 136.16 | 139.24 | 1.43M |
| Sep 14, 2026 | 134.23 | 137.98 | 131.61 | 137.80 | 2.34M |
| Sep 11, 2026 | 135.40 | 135.57 | 131.24 | 131.96 | 1.75M |
| Sep 10, 2026 | 136.74 | 138.66 | 134.11 | 134.68 | 1.87M |
| Sep 09, 2026 | 140.26 | 142.69 | 137.25 | 137.92 | 2.06M |
| Sep 08, 2026 | 147.39 | 147.39 | 139.27 | 142.28 | 2.22M |
| Sep 04, 2026 | 149.32 | 150.56 | 145.42 | 147.48 | 1.06M |
| Sep 03, 2026 | 148.14 | 150.99 | 145.16 | 150.58 | 1.15M |
| Sep 02, 2026 | 148.00 | 151.50 | 147.21 | 148.14 | 1.09M |
| Sep 01, 2026 | 149.79 | 151.16 | 146.81 | 148.38 | 1.29M |
| Aug 31, 2026 | 142.93 | 149.68 | 142.01 | 148.66 | 6.62M |
| Aug 28, 2026 | 144.20 | 146.67 | 143.81 | 145.13 | 1.04M |
| Aug 27, 2026 | 142.96 | 144.60 | 140.98 | 143.41 | 1.34M |
| Aug 26, 2026 | 141.27 | 144.64 | 141.23 | 143.38 | 1.42M |
| Aug 25, 2026 | 145.28 | 146.10 | 141.78 | 143.05 | 1.93M |
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
| Employees | 5400 |
| Beta | 1.08 |
| Sales or Revenue | $1.70B |
| 5Y Sales Change% | 1.54% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Medical - Devices |